All News
Filter News
Found 808,645 articles
-
Agilex Biolabs and B2S Life Sciences on Immunoassay Bioanalysis for Clinical Trials
4/29/2021
Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics, shared key ways to navigate the immunogenicity and biomarker requirements for clinical trials via webinar.
-
Vaccitech Announces Pricing of Initial Public Offering
4/29/2021
Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public offering price of $17.00 per ADS
-
Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis
4/29/2021
Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022
-
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
4/29/2021
Werewolf Therapeutics, Inc. (NASDAQ: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the pricing of its upsized initial public offering of 7,500,000 shares of common stock at a public offering price of $16.00 per share
-
Genocea Provides First Quarter 2021 Corporate Update
4/29/2021
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens ™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) --
-
Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights
4/29/2021
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– –Announced strategic collaboration with Abdul Latif Jameel Health to develop and commercialize EDP1815 in select developing markets– –Multiple clinical data readouts expected over next 18 months– –Management to host conference call at 8:30
-
Acceleron Announces First Quarter 2021 REBLOZYL® Net Sales
4/29/2021
Acceleron Announces First Quarter 2021 REBLOZYL ® Net Sales - Acceleron expects to report approximately $22.4 million in royalty revenue for Q1 2021 from approximately $112 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb -
-
Blueprint Medicines Reports First Quarter 2021 Financial Results
4/29/2021
-- 7 research- and clinical-stage programs highlighted at AACR, including recently nominated development candidate with best-in-class potential targeting CDK2 -- -- GAVRETO® (pralsetinib) becomes the first selective RET inhibitor approved in China; AYVAKIT™/AYVAKYT® (avapritinib) becomes the first precision therapy for patients with PDGFRA exon 18 mutant GIST in China --
-
Abiomed Announces Record Revenue of $241 Million, up 17% Year Over Year, With 26.0% Operating Margin
4/29/2021
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported record fourth quarter fiscal 2021 revenue of $241.2 million compared to revenue of $206.7 million for the same period of fiscal 2020, driven by a record number of patients supported.
-
Curative Biotechnology, Inc. Announces FINRA Ticker Symbol Change From CTYX To CUBT
4/29/2021
Company Announces Addition of Dr. Kapil Bharti and Dr. Dimiter Dimitrov to Scientific and Clinical Advisory Board
-
Linshom Receives SBIR Phase II contract award from the United States Air Force for its Dual Purpose Respiratory Device
4/29/2021
Linshom announced today receipt of a phase II SBIR contract award with the United States Air Force (USAF) to fund ongoing development and deployment of the Linshom Predictive Continuous Respiratory Monitoring (LPCRM) System.
-
Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan
4/29/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into a securities purchase agreement with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering.
-
Insight Medbotics appoints new President & CEO
4/29/2021
The Board of Directors for Insight Medbotics, a start-up founded by MDA and the Centre for Surgical Invention and Innovation (CSii), are pleased to announce the appointment of Paul Chipperton as the company's Chief Executive Officer & President.
-
Cerapedics Announces FDA Breakthrough Device Designation Granted for P-15L Bone Graft for the Treatment of Degenerative Disc Disease
4/29/2021
Cerapedics Inc., an ortho-biologics company dedicated to enhancing the science of bone repair, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for its investigational P-15L Bone Graft for the treatment of degenerative disc disease (DDD).
-
City of Hope Opens Phase 2 Clinical Trial to Test If Intake of Mushroom-Powder Tablets Could Slow the Progression of Prostate Cancer
4/29/2021
Scientists investigate if City of Hope’s natural supplement derived from white button mushroom could lower prostate-specific antigen levels, an indicator of prostate cancer.
-
Sirnaomics Enters Partnership with Walvax Biotechnology to Co-Develop Its Antiviral RNAi Therapeutic Product Candidate STP702
4/29/2021
Sirnaomics Biopharmaceuticals (Suzhou) Co. Ltd., a subsidiary of Sirnaomics, Inc ., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer, fibrotic diseases and viral infections, announced today that the company has entered into a partnership agreement with Walvax Biotechnology
-
Dr. Reddy's Laboratories Announces the Launch of Albendazole Tablets, USP in the U.S. Market
4/29/2021
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Albendazole Tablets, USP, a therapeutic equivalent generic version of Albenza Tablets, 200 mg, approved by the U.S. Food and Drug Administration (USFDA).
-
Elucida Oncology Announces Three Key Additions to Its Board of Directors and the Appointment of Robert Essner as Chairman of the Board
4/29/2021
Elucida Oncology, a biotechnology company pioneering the next frontier in targeted cancer therapy, announced today three key additions to its Board of Directors: Dr. David Zaccardelli, Ms. Natalie McDonald, and Mr. Gary Sender.
-
Ceribell Announces Completion Of $53 Million Series C Financing
4/29/2021
Proceeds will be used to expand commercialization of the Ceribell Rapid Response EEG and support pipeline product development to drive future clinical applications
-
Vascular Therapies Announces Clinical Results From Its Phase 3 Randomized Multicenter Clinical Trial
4/29/2021
Vascular Therapies, a privately held biotechnology company is developing Sirogen™, a proprietary sirolimus formulation for intraoperative local drug delivery to reduce surgical stenosis in blood vessels.